The approval allows Vivos to begin in-house manufacturing of IsoPet and supports broader commercialization of its veterinary cancer treatment platform.
Key Investor Takeaways
- Vivos Inc. (USOTC:RDGL) received a Washington State Radioactive Materials License for manufacturing IsoPet®.
- The approval enables domestic production at the company’s new facility in Richland, Washington.
- Management expects the first production run to ship in the near future.
- The company plans to seek a license amendment to add RadioGel®, supporting future human clinical trial activities.
- The milestone advances Vivos’ strategy to scale production and expand access to its Precision Radionuclide Therapy™ platform.
Why RDGL Stock Is In Focus
Vivos announced that it has obtained a Washington State Radioactive Materials License authorizing the manufacture of IsoPet®, the company’s Yttrium-90-based cancer treatment for companion animals and horses.
The license permits production at the company’s new manufacturing facility located within the Applied Process Engineering Laboratory (APEL) in Richland, Washington.
According to management, the approval establishes compliant domestic manufacturing capabilities and positions the company to begin commercial-scale production. Vivos stated that it expects to ship its first production run in the near future.
The company also disclosed plans to immediately pursue an amendment to the license that would add RadioGel®, its human-focused cancer therapy platform, to support future clinical trial activities in the United States and potentially abroad.
Why This Matters for Investors
For healthcare companies developing regulated medical technologies, manufacturing approvals can represent important commercialization milestones.
The newly granted license removes a regulatory hurdle and provides Vivos with the ability to manufacture IsoPet internally, which may improve production control, supply reliability, and scalability as demand grows.
The announcement is particularly relevant because it moves the company from preparation toward operational execution. Management indicated that the approval will support expansion of certified IsoPet treatment centers and broader access to the therapy for veterinary oncology patients.
The planned addition of RadioGel to the license may also be significant. While the current approval is focused on the animal health business, the amendment process could help support future clinical development efforts for the company’s human cancer treatment platform.
Investors will likely view the regulatory approval as an operational milestone that advances both commercialization and longer-term development objectives.
What To Watch Next
Key catalysts investors may monitor include:
- Shipment of the first IsoPet production batches.
- Expansion of certified IsoPet treatment centers.
- Growth in adoption among veterinary oncology providers.
- Progress on the planned RadioGel license amendment.
- Updates regarding U.S. and international clinical trial activities.
- Additional regulatory and manufacturing milestones supporting commercialization.
The next major milestone will likely be the launch of production from the Richland facility and the company’s ability to scale IsoPet availability across its growing treatment network.